

In Brief: Four Newer Antidepressants

Brand name	Ketalar	Brintellix	Fetzima	Viibryd
Generic name	ketamine	vortioxetine	levomilnacipran	vilazodone
Generic available?	Yes	No	No	No
Manufacturer	Multiple	Takeda / Lundbeck	Actavis	Actavis
Initial approval date	February 19, 1970	September 30, 2013	July 26, 2013	January 21, 2011
FDA indications	General anesthesia	Major depression	Major depression	Major depression
Dosages available	10, 50, 100 mg/ml (IV)	5, 10, 20 mg	20, 40, 80, 120 mg	10, 20, 40 mg
Dosing for depression	Not established	10–20 mg QD	40–120 mg QD	20–40 mg QD
Average cost	\$500+ (per infusion)	\$300 per month	\$300 per month	\$220 per month
Likely marketing points	Rapid response; efficacy for refractory patients	Cognitive improvement	Functional improvement; “norepinephrine depression” specific	Lack of sexual side effects; improvement in anxiety
Comments	Controlled substance: C III	FDA has denied approval of cognitive claims	No evidence of advantages over existing agents	Claims not yet substantiated

From the full article:
“Four Newer Antidepressants: Should You Use Them?”
 by Steve Balt, MD and Talia Puzantian, PharmD, BCPP
The Carlat Psychiatry Report, Volume 14, Number 4, April 2015
www.thecarlatreport.com